New Study Reveals Promising Results for Gastric Cancer Treatment

Strategic Insights -

A recent study published in Frontiers in Immunology has shed new light on the treatment of locally advanced gastric cancer. Researchers from Nankai University have developed and validated a nomogram model to predict pathological complete response (pCR) in patients receiving neoadjuvant chemotherapy and immunotherapy (NICT). The study, which enrolled 456 patients from seven large-scale gastrointestinal medical centers in China, found that the NICT combination resulted in a higher proportion of pCR compared to neoadjuvant chemotherapy alone.

Key Takeaways:

  • The nomogram model developed by the researchers was able to predict pCR in locally advanced gastric cancer patients with NICT, with an area under the receiver operating characteristic curve (AUC) of 0.83.
  • The model included factors such as complete response by abdominal enhanced CT, less diameter of tumor bed, non-signet-ring cell, ages 70 years old, and CEA levels.
  • The study found that the pCR rate was 16.2%, with 39.5% of patients achieving a major pathologic response (MPR).
  • The nomogram model was able to provide satisfactory predictive effect for pCR in LAGC patients with NICT, which proves to be a valuable approach for surgeons to make personalized strategies.
  • The study concluded that the combination of neoadjuvant chemotherapy and immunotherapy is a promising treatment approach for locally advanced gastric cancer.
  • Rui Li, School of Medicine, Nankai University, Tianjin, People's Republic of China, was the lead researcher on the study.
  • Additional authors included Hao Cui, Liqiang Song, Yongpu Yang, Zhen Yuan, Xin Zhou, Junfeng Du, Chaojun Zhang, Hong Xu, Lin Chen, Yan Shi, Jianxin Cui, and Bo Wei.

Statistics:

  • pCR rate: 16.2%
  • MPR rate: 39.5%
  • Number of patients enrolled: 456
  • Number of patients in training set: 320
  • Number of patients in validation set: 136
  • Area under the receiver operating characteristic curve (AUC): 0.83

Sources:

  • "Development and validation of nomogram for predicting pathological complete response to neoadjuvant chemotherapy and immunotherapy for locally advanced gastric cancer: a multicenter real-world study in China." Frontiers in Immunology, 2025;16:1603196.
  • Frontiers Media Sa, Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland (Publisher)